Longevity Peptides: BPC-157, MOTS-C, TB-500 and What We Still Do Not Know

The promise is wonderfully tidy: recover faster, gain energy and perhaps age better at the same time. Add a vial and a scientific-sounding name, and it can feel as though you are looking at the next major medical advance. That is how BPC-157, MOTS-C and TB-500 often appear in clinics, social feeds and biohacking communities.

The honest answer is less dramatic and much more useful: none has been shown to extend life, improve healthspan or prevent an age-related disease in people. BPC-157 has a few tiny human reports. For MOTS-C and TB-500 products, FDA still described an absence of identified human exposure data in its safety review. There is no validated longevity dose for any of them.

That does not make every line of research silly. It means a promising hypothesis is not yet a treatment. Let us mark the point where the evidence ends and the leap of faith begins.

The short answer, peptide by peptide

Substance	Common promise	What we know in humans	Practical conclusion
BPC-157	Tendon, gut and joint repair.	Small, short pilot studies that cannot establish tissue repair or long-term safety. No longevity trial.	Do not treat it as proven therapy. Uncertainty remains high.
MOTS-C	Better metabolism, insulin sensitivity and performance.	Cell biology, animal studies and measurements of the MOTS-C made by the body. No demonstrated clinical benefit from the injected product.	Investigational. A mitochondrial mechanism is not a patient outcome.
TB-500	Faster wound, muscle or tendon recovery.	No human trial demonstrates efficacy of the fragment marketed as TB-500.	Investigational. Its benefit-risk balance is unknown.
Combinations	Stacking BPC-157 and TB-500 to amplify results.	No human trial validates the efficacy, interaction or safety of these stacks.	Combining uncertainties does not create evidence and makes the cause of harm harder to identify.

“Peptide” does not mean “safe” or “effective”

A peptide is a short chain of amino acids. Insulin and other peptide drugs show that this family can produce excellent medicines. Every approved product, however, had to establish what it contains, how it is made, what dose reaches the body, whom it helps and what harm it can cause.

Sharing the word “peptide” does not transfer that evidence to another molecule. It is like assuming every tablet works because one tablet works. Our guide to longevity treatments and levels of evidence uses a simple ladder: mechanism, biomarker, function and clinical outcome are not interchangeable.

BPC-157: human data, yes; proof of benefit, no

BPC-157 is a synthetic 15-amino-acid peptide. Researchers have explored possible effects on healing, blood vessels and injured tissues in animals. That is a good reason to investigate. It is not enough reason to inject it into people as if efficacy were settled.

The published human evidence fits around a small table:

• Bladder pain: one pilot included 12 women with interstitial cystitis. They received a procedure involving 10 mg and reported improvement at six weeks, but there was no placebo, blinding or comparison group. An open series cannot separate the product effect from selection, expectation or the natural course of symptoms.
• Immediate intravenous safety: another pilot gave 10 mg and 20 mg to two adults who had used BPC-157 before. No problem was observed over brief follow-up. Two people cannot reveal uncommon, cumulative or long-term effects.
• Injuries and longevity: no controlled trial shows tendon repair, a faster return to sport or a longer and healthier life.

The accurate sentence is not “BPC-157 works” or “BPC-157 is toxic”. It is this: we still do not know whether it provides a clinical benefit, and its safety is also poorly characterised.

MOTS-C: what the body makes is not the same experiment as a vial

MOTS-C is a peptide encoded by mitochondrial DNA. Cell, animal and human measurement studies have linked it to AMPK, metabolism, exercise and stress adaptation.

The leap occurs when those observations become “injecting it improves metabolism”. Endogenous MOTS-C and a synthetic product administered from outside are not equivalent experiments. FDA's evaluation identified no human exposure data for MOTS-C drug products and no clinical pharmacokinetics that could tell us what concentration is reached or how long it lasts.

We therefore cannot give a human effect size, a useful regimen or a reliable risk profile. There is an interesting hypothesis and a long list of unanswered questions.

TB-500: a fragment does not inherit the full protein's results

TB-500 usually refers to LKKTETQ, a seven-amino-acid fragment related to thymosin beta-4. The full protein has been investigated in other settings, but a fragment can have different stability, distribution and activity.

Using thymosin beta-4 studies to sell TB-500 is like showing the manual for a similar car and insisting that it describes yours. FDA's review found no published human exposure to the TB-500 fragment. We do not know whether a vial matches its label, what exposure it creates or what systemic effects it could have.

What the 2026 FDA vote actually meant

In July 2026, an external FDA advisory committee voted narrowly to recommend several of these substances for a list of ingredients that may be used in US pharmacy compounding. The meeting examined specific proposed uses, including ulcerative colitis, wound healing, obesity and osteoporosis. It did not assess longevity.

The distinction matters:

• an advisory committee makes a non-binding recommendation;
• compounding is preparation under a specific framework, not premarket approval of a finished medicine;
• the vote did not validate an indication, dose, brand or clinic protocol;
• FDA's safety page continued to flag immunogenicity, impurities, aggregation and missing human information.

In short, “a panel voted in favour” does not mean “FDA approved these peptides”. Those are very different statements.

Why you will not find a dosing protocol here

A clinical dose is not created by counting which number appears most often in forums. Studies must connect amount, route, concentration in the body, response, toxicity and interactions. BPC-157 has been explored through very different routes, including the bladder and intravenous infusion. Those doses cannot be swapped. MOTS-C and TB-500 lack the published human foundation needed to construct a regimen at all.

A 5 mg vial does not show that 5 mg is effective, safe or appropriate. It only states what a vendor says is in the container. A stack adds another layer: if a reaction occurs, it may be impossible to separate the peptide from an impurity, contamination, excipient or combination effect.

The risks begin before the first injection

• Identity and potency: the name, salt form and true concentration may not match the label.
• Sterility and endotoxins: a contaminated injectable can cause a serious infection even if the theoretical molecule were harmless.
• Impurities and aggregates: synthesis and degradation can create variants that change exposure or activate the immune system.
• Allergy and immunogenicity: the true frequency is not quantified.
• Interactions: there are too few data to predict what happens alongside medicines, supplements or other peptides.
• Opportunity cost: the experiment can delay a diagnosis, a well-designed rehabilitation plan or a treatment with demonstrated benefit.

When to seek urgent help

Seek urgent care after an injection if you develop breathing difficulty, lip or tongue swelling, fainting, chest pain, confusion, high fever, severe pain or spreading redness. A hot lump, discharge, widespread rash, dark urine or yellowing of the eyes or skin also deserves prompt assessment.

If you have already used one, document it instead of blaming yourself

Hiding it out of embarrassment only makes assessment harder. Keep the vial, box and any certificate; write down the product name, batch, approximate dose, route, dates and symptoms. Do not use it again to see whether a reaction repeats.

A clinician can decide whether symptoms suggest infection, allergy, liver injury or another problem. There is no universal blood panel that removes every uncertainty, so the timing and clinical story matter more than ordering a huge set of random tests.

For athletes, this is not only a medical question

The 2026 anti-doping list includes BPC-157, TB-500 and MOTS-C in categories prohibited at all times. Uncertain labelling also creates a contamination risk from other substances. Anti-doping responsibility does not disappear because a clinic recommended the product or the label said “research only”.

Start with the goal, not the peptide

If your goal is...	Define first...	Better-supported options
Recover a tendon or joint	Diagnosis, function, tolerated load, strength and red flags.	Progressive rehabilitation, load adjustment, indicated analgesia and referral for rupture, locking or neurological deficit.
Improve metabolism or weight	Baseline risk, waist, blood pressure, glucose, lipids, sleep and medication.	Nutrition, activity, sleep and approved treatment when there is a clear indication.
Preserve muscle with age	Strength, function, intake, disease and medication.	Progressive resistance training, adequate protein and treatment of causes. Our guide to sarcopenia and muscle loss shows where to begin.
Live longer and better	The outcome you want to change and your absolute risk.	Blood pressure, lipids, glucose, exercise, sleep, vaccines and indicated screening.

Seven questions before you pay

1. What is the diagnosis, and which clinical outcome should improve?
2. Which controlled human trial supports this exact product, route and dose?
3. What absolute benefit should I expect, and over what period?
4. Who made the finished product?
5. How were identity, potency, sterility, endotoxins and aggregation tested?
6. What are the stopping rules, and how is an adverse reaction reported?
7. Which better-supported alternatives were considered?

“It activates your mitochondria”, “everyone uses this dose” and “it is natural, so there are no side effects” answer none of them. Our guide to choosing a longevity clinic provides a fuller filter.

Frequently asked questions

Is BPC-157 approved for human use?

It is not an FDA-approved medicine or an authorised longevity treatment. The 2026 advisory vote concerned a possible US compounding route; it did not approve the product, an indication or a dose.

What BPC-157 benefits have been proven in humans?

It has not been shown to extend life, repair tendons or accelerate recovery. Published human data come from very small pilot studies and cannot establish efficacy or long-term safety.

Is there a safe dose of BPC-157, MOTS-C or TB-500?

There is no validated longevity dose for any of the three. A regimen repeated by vendors or on social media cannot replace dose-ranging, pharmacokinetic, efficacy and safety studies.

Does MOTS-C improve metabolism or exercise performance?

The MOTS-C made by the body is involved in metabolic processes, and animal experiments are interesting. FDA identified no published human exposure to MOTS-C drug products, so clinical benefit, dosing and safety remain unknown.

Is TB-500 the same as thymosin beta-4?

Not exactly. TB-500 usually refers to a seven-amino-acid fragment related to thymosin beta-4. Results obtained with the full protein do not show that the fragment sold as TB-500 behaves the same way.

What does research use only mean on a vial?

It means the material is sold for research, not administration to people. That label does not certify identity, purity, concentration, sterility or clinical safety.

Are these peptides prohibited in sport?

The 2026 anti-doping list includes BPC-157, TB-500 and MOTS-C in categories prohibited at all times. Mislabelling or a clinic recommendation does not remove the risk of a sanction.

What should I do if I have already injected one of these products?

Do not repeat the dose to test a reaction. Keep the vial and batch details, record the amount, route and date, and tell a healthcare professional. Seek urgent care for breathing difficulty, fainting, high fever or a severe reaction.

Sources reviewed

• FDA, bulk substances for compounding that may present significant risks: safety and human-exposure gaps for BPC-157, MOTS-C and TB-500.
• FDA, July 2026 Pharmacy Compounding Advisory Committee meeting: reviewed uses, scientific documents and the advisory role of the committee.
• Associated Press, FDA panel vote: narrow result and non-binding nature of the recommendation.
• BPC-157 pilot in interstitial cystitis: 12 participants, one procedure and no comparison group.
• BPC-157 intravenous safety pilot: two adults and brief follow-up.
• Review of approved and unapproved peptides in injury and sport: scarce human evidence and a framework for clinical discussion.
• USADA, BPC-157 and athlete risk: anti-doping status and lack of clinical approval.
• USADA, 2026 WADA Prohibited List: access to the current list and its categories.

The final idea is simple: a molecule can deserve serious research without deserving the status of medicine. In longevity, saying “we do not know yet” is not falling behind. It is often the most modern and careful decision available.